<DOC>
	<DOCNO>NCT03097835</DOCNO>
	<brief_summary>The purpose study comprehensively investigate objectively demonstrate effectiveness hyperdiltue Botox® Cosmetic improve overall skin quality , specifically evenness skin tone , reduction pore size improvement appearance preexist skin scar .</brief_summary>
	<brief_title>Evaluation Skin Quality Improvement</brief_title>
	<detailed_description>The purpose study comprehensively investigate objectively demonstrate effectiveness hyperdiltue Botox® Cosmetic improve overall skin quality , specifically evenness skin tone , reduction pore size improvement appearance preexist skin scar . The ability hyperdilute Botox® Cosmetic improve overall skin quality likely optimize inject uniformly hyper-diluted small aliquot order `` saturate '' dermis . We propose prepare Botox® Cosmetic manner approximately 4 time dilute compare typical Botox® Cosmetic preparation . A 4x4 centimeter area locate mid-cheek adjacent nose inject hyperdilute Botox® Cosmetic . Botox® Cosmetic FDA-approved use . A maximum 15 subject participate study , receive injection Botox® Cosmetic course study . This study randomize , placebo-controlled , double-masked study . This mean neither study doctor participant know experimental agent ( e.g. , 0.9 % saline solution hyperdiluted Botox® Cosmetic ) inject side patient ' face . The study last total 75 day . Evaluation study base analysis photographic image obtain study .</detailed_description>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Anesthetics</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<criteria>Ability follow study instruction likely complete require visit Written consent obtain Written authorization `` Use Release Health Research Study Information '' obtain Subjects Fitzpatrick Skin Types IIIV Subjects must Onabotulinum Toxin Type A naive ; subject Onabotulinum Toxin Type A administer face previous 12 month exclude Subjects must dermal filler naïve lateral canthal region midface region Subjects must energy light device naïve Subjects must average belowaverage lifetime sun exposure Subjects must free inflammatory skin disease ( )</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>